AACR-NCI-EORTC to hold molecular targets meeting in San Francisco

Public release date: 9-Nov-2011
[ | E-mail | Share ]

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research

SAN FRANCISCO -- Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics.

"During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer," said program co-chairperson Kenneth C. Anderson, M.D., Kraft Family professor of medicine and program director and chief of the division of hematologic neoplasia at Dana-Farber Cancer Institute and Harvard Medical School. "The level of excitement surrounding targeted therapy and the high caliber of the science to be presented fuel the power of this meeting to attract the world's leaders in cancer therapeutics."

Anderson, who is also editor in chief of Clinical Cancer Research, a journal of the American Association for Cancer Research, will host a press conference on new research in breast cancer at 7:00 a.m. PT on Sunday, Nov. 12.

The press conference will feature the following research:

HDAC Inhibitor May Overcome Resistance to Common Breast Cancer Drug

Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks

Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis

On Nov. 12 at 11:00 a.m. PT, program co-chairperson James H. Doroshow, M.D., FACP, deputy director for clinical and translational research at the National Cancer Institute, will host a press conference on progress in angiogenesis.

The press conference will feature the following research:

Researchers Develop More Effective Way to Discover and Test Potential Cancer Drugs

Novel Monoclonal Antibody Offers Potential Treatment for Tumors Resistant to VEGF Therapy

Combination Therapy Shows Potent Tumor Growth Inhibition in Preclinical Studies

Both press conferences will take place in Room 2004 of the Moscone Center. Reporters who cannot attend in person can call in using the following information:

U.S./Canada: 888-647-7462

International: 201-604-0169

In addition to the press conference, the program chairpersons have designated the following research projects as newsworthy:

Antifolates Show Promise Against NSCLC Subtype

New Approaches May Prevent Certain Side Effects in BRAF Mutation-Positive Melanoma

Panel of Melanoma Mutations Opens Door to New Treatment Possibilities

###

Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards to young investigators, and it also funds cutting-edge research projects conducted by senior researchers.

The AACR has numerous fruitful collaborations with organizations and foundations in the U.S. and abroad, and functions as the Scientific Partner of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care, and Educational Workshops are held for the training of young cancer investigators.

The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. In 2010, AACR journals received 20 percent of the total number of citations given to oncology journals. The AACR also publishes Cancer Today, a magazine for cancer patients, survivors and their caregivers, which provides practical knowledge and new hope for cancer survivors. A major goal of the AACR is to educate the general public and policymakers about the value of cancer research in improving public health, the vital importance of increases in sustained funding for cancer research and biomedical science, and the need for national policies that foster innovation and the acceleration of progress against the 200 diseases we call cancer.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 9-Nov-2011
[ | E-mail | Share ]

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research

SAN FRANCISCO -- Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics.

"During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer," said program co-chairperson Kenneth C. Anderson, M.D., Kraft Family professor of medicine and program director and chief of the division of hematologic neoplasia at Dana-Farber Cancer Institute and Harvard Medical School. "The level of excitement surrounding targeted therapy and the high caliber of the science to be presented fuel the power of this meeting to attract the world's leaders in cancer therapeutics."

Anderson, who is also editor in chief of Clinical Cancer Research, a journal of the American Association for Cancer Research, will host a press conference on new research in breast cancer at 7:00 a.m. PT on Sunday, Nov. 12.

The press conference will feature the following research:

HDAC Inhibitor May Overcome Resistance to Common Breast Cancer Drug

Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks

Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis

On Nov. 12 at 11:00 a.m. PT, program co-chairperson James H. Doroshow, M.D., FACP, deputy director for clinical and translational research at the National Cancer Institute, will host a press conference on progress in angiogenesis.

The press conference will feature the following research:

Researchers Develop More Effective Way to Discover and Test Potential Cancer Drugs

Novel Monoclonal Antibody Offers Potential Treatment for Tumors Resistant to VEGF Therapy

Combination Therapy Shows Potent Tumor Growth Inhibition in Preclinical Studies

Both press conferences will take place in Room 2004 of the Moscone Center. Reporters who cannot attend in person can call in using the following information:

U.S./Canada: 888-647-7462

International: 201-604-0169

In addition to the press conference, the program chairpersons have designated the following research projects as newsworthy:

Antifolates Show Promise Against NSCLC Subtype

New Approaches May Prevent Certain Side Effects in BRAF Mutation-Positive Melanoma

Panel of Melanoma Mutations Opens Door to New Treatment Possibilities

###

Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards to young investigators, and it also funds cutting-edge research projects conducted by senior researchers.

The AACR has numerous fruitful collaborations with organizations and foundations in the U.S. and abroad, and functions as the Scientific Partner of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care, and Educational Workshops are held for the training of young cancer investigators.

The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. In 2010, AACR journals received 20 percent of the total number of citations given to oncology journals. The AACR also publishes Cancer Today, a magazine for cancer patients, survivors and their caregivers, which provides practical knowledge and new hope for cancer survivors. A major goal of the AACR is to educate the general public and policymakers about the value of cancer research in improving public health, the vital importance of increases in sustained funding for cancer research and biomedical science, and the need for national policies that foster innovation and the acceleration of progress against the 200 diseases we call cancer.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2011-11/aafc-ath110911.php

history of halloween eagles cowboys eagles cowboys rock center trick or treat times trick or treat times madoff